Cashu
Precigen Develops PAPZIMEOS™ for Treating Respiratory Papillomatosis and Advances in Immunology
1 day ago
Stocks
Health Care
pgen
Precigen
NASDAQ: PGEN
+0.01 (+0.25%)
3.94
USD
At close at Apr 03, 18:07 UTC
Latest Precigen News
prnewswire.com
Precigen to Participate in a Fireside Chat with H.C. Wainwright on March 31
4 days ago
benzinga.com
These Analysts Boost Their Forecasts On Precigen Following Q4 Results
8 days ago
benzinga.com
Earnings Scheduled For March 25, 2026
9 days ago
prnewswire.com
New Expert Consensus Published in The Laryngoscope Recommends PAPZIMEOS (zopapogene imadenovec) as the New Standard of Care First-Line Treatment for Adults with Recurrent Respiratory Papillomatosis
2 months ago
prnewswire.com
Precigen Showcases Rapid Commercialization Momentum and Growing Market Adoption of First-and-Only FDA-Approved Therapy for RRP at the 44th Annual J.P. Morgan Healthcare Conference
3 months ago
benzinga.com
Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 42%? Here Are Other Stocks Moving In Monday's Mid-Day Session
3 months ago
benzinga.com
DigitalBridge Group, Eightco Holdings, Palisade Bio And Other Big Stocks Moving Higher On Monday
3 months ago
benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
5 months ago
benzinga.com
Earnings Scheduled For November 13, 2025
5 months ago
prnewswire.com
Precigen Announces Long-Term Follow-Up Results Highlighting Ongoing Durable Complete Responses after Treatment with PAPZIMEOS, the First and Only FDA-approved Therapy for Adults with Recurrent Respiratory Papillomatosis
6 months ago
Join our newsletter to keep up to date with us!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.